OKYO Stock Overview
A clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
OKYO Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.04 |
| 52 Week High | US$2.12 |
| 52 Week Low | US$0.81 |
| Beta | -3.36 |
| 11 Month Change | -8.78% |
| 3 Month Change | -21.80% |
| 1 Year Change | -38.64% |
| 33 Year Change | -72.51% |
| 5 Year Change | n/a |
| Change since IPO | -53.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| OKYO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.8% | 4.0% | 2.0% |
| 1Y | -38.6% | 18.0% | 32.4% |
Return vs Industry: OKYO underperformed the US Biotechs industry which returned 18% over the past year.
Return vs Market: OKYO underperformed the US Market which returned 32.4% over the past year.
Price Volatility
| OKYO volatility | |
|---|---|
| OKYO Average Weekly Movement | 11.9% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: OKYO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: OKYO's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 3 | Gary Jacob | okyopharma.com |
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease; in phase 1 clinical trial for the treatment of neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201, which is in preclinical trial for the treatment of dry eye disease and neuropathic chronic pain.
OKYO Pharma Limited Fundamentals Summary
| OKYO fundamental statistics | |
|---|---|
| Market cap | US$35.53m |
| Earnings (TTM) | -US$16.83m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.1x
P/E RatioIs OKYO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OKYO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$7.51m |
| Gross Profit | -US$7.51m |
| Other Expenses | US$9.32m |
| Earnings | -US$16.83m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.50 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did OKYO perform over the long term?
See historical performance and comparison